South Dakota Patent of the Month – June 2024
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, has developed a groundbreaking method to combat COVID-19 using transgenic ungulates, specifically engineered bovines, to produce polyclonal human immunoglobulins. Unlike traditional approaches relying on human or animal plasma, their innovative technique involves administering SARS-CoV-2 spike protein antigens to these genetically modified animals. This stimulates the production of fully human immunoglobulin G (IgG) in their serum and plasma, a crucial advancement in therapeutic antibody development.
What sets this method apart is its use of the Transchromosomal Bovine (TcB) system, which incorporates human immunoglobulin loci while knocking out the bovine counterparts. This ensures that the produced immunoglobulins closely mimic those naturally found in humans, potentially enhancing efficacy and safety. Moreover, the process includes multiple immunizations to optimize antibody production, reflecting meticulous planning and scientific rigor.
One of the notable advantages of SAB Bio’s approach lies in the glycosylation profile of the antibodies. Their research indicates that these polyclonal human immunoglobulins exhibit desirable glycan compositions, including a significant presence of N-Glycolylneuraminic acid (NGNA)-bearing glycans. This feature not only enhances the antibodies’ effector functions but also potentially improves their therapeutic effectiveness compared to existing treatments.
The method addresses critical safety concerns associated with animal-derived immunoglobulins, such as hypersensitivity reactions and serum sickness. By utilizing genetically modified ungulates, SAB Bio mitigates these risks while ensuring a robust supply of therapeutic antibodies for COVID-19 treatment.
SAB Bio’s innovative approach represents a significant leap forward in the field of biotechnology and immunotherapy. Their method not only meets the urgent global need for effective COVID-19 treatments but also lays the groundwork for future advancements in therapeutic antibody production.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
